BRIEF-US FDA staff raises questions on Human Genome, Glaxo lupus drug

WASHINGTON, Nov 12 (Reuters) - U.S. Food and Drug Administration staff, in documents released on Friday, said: * Various analyses of data on Human Genome Sciences Inc lupus drug Benlysta 'raise questions about the robustness of the efficacy findings' * Benlysta data 'not adequate to demonstrate efficacy in organ involvement associated with poor outcome and mortality' * Post-hoc analysis of racial subgroups given Benlysta suggest there may be reversal in direction of treatment effect in patients of African American or African heritage * Data on Human Genome, Glaxosmithkline lupus drug Benlysta 'demonstrate an inconsistent efficacy trend across different geographical regions' * Potentially slower onset of benefit and a potential lack of durability need to be considered with Benlysta * Part of study design 'may have exaggerated' difference between placebo and Benlysta for the primary endpoint analysis * Safety issues that warrant discussion at Benlysta advisory panel include deaths,infections, malignancy, suicide, infusion reactions * Robustness and clinical meaning of Benlysta efficacy findings warrant discussion * Will ask advisory panel if degree of efficacy demonstrated in Benlysta trials is worth the risks * Will ask panel if potential benefits of Benlysta outweigh anticipated risk of treatment if drug is combined with other immunosuppressive agents (Company news desk in Washington; +1 202 898 8400, COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved.

The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.